rabbit anti-Vimentin monoclonal antibody (BLR100G) 9046

$409.00

Antibody summary

Rabbit monoclonal to Vimentin
Suitable for: WB, ICC/IF, IHC
Reacts with: human, mouse, rat
Isotype: IgG
100 µg

SKU: 9046 Categories: antibody, cell marker Tag: vimentin

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	rabbit
isotype	IgG
clonality	monoclonal
concentration	1 mg/mL
applications	ICC/IF, IHC, WB
available sizes	100 µg

rabbit anti-Vimentin monoclonal antibody (BLR100G) 9046

antibody
Database link: human P08670 mouse P20152 rat P31000
Tested applications WB,IHC,IHC,ICC/IF
Recommended dilutions Western blot: 1:10000 IF/ICC and IHC: 1:5000
Immunogen Full length human TH expressed in and purified from E. coli.
Size and concentration 100µg and 1 mg/mL
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Storage buffer PBS, 50% glycerol, 0.04% NaN₃
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit monoclonal - Isotype Control

target relevance
Vimentin, a key protein constituent of the intermediate filament cytoskeleton, plays a pivotal role in maintaining cellular integrity and structure. In research, vimentin has become a valuable biomarker due to its tissue-specific expression and involvement in various cellular processes. Immunohistochemical analysis of vimentin has been extensively utilized to identify and characterize mesenchymal cells, such as fibroblasts, endothelial cells, and immune cells, aiding in the study of tissue development, wound healing, and cancer progression. Additionally, vimentin has been linked to epithelial-mesenchymal transition (EMT), a critical process implicated in embryonic development and metastasis. Furthermore, efforts to develop vimentin-targeting therapies for cancer treatment have shown promise, as vimentin's involvement in EMT and tumor progression make it a potential therapeutic target for limiting cancer metastasis. Click for more on: cell markers and Vimentin
Protein names Vimentin
Gene names VIM,VIM
Protein family Intermediate filament family
Mass 53652Da
Function Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. ; Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.
Subellular location Cytoplasm Cytoplasm, cytoskeleton Nucleus matrix Cell membrane
Tissues Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.
Structure Homomer assembled from elementary dimers (PubMed:20176112). Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with BCAS3 (PubMed:17505058). Interacts with LGSN (By similarity). Interacts with SYNM (By similarity). Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with PLEC isoform 1C (PubMed:24940650). Interacts with STK33 (PubMed:18811945). Interacts with LARP6 (PubMed:21746880). Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton (PubMed:16361107, PubMed:18827015). Interacts with TOR1AIP1 (PubMed:16361107). Interacts with DIAPH1 (PubMed:23325789). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament (PubMed:16923132). Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM (PubMed:29496907). Interacts with NOD2 (PubMed:27812135). Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2) (PubMed:26845719). Interacts with PRKCE (via phorbol-ester/DAG-type 2 domain) (PubMed:18408015). Interacts with BFSP2 (By similarity). Interacts with PPL (By similarity). Interacts (via rod domain) with PKP1 (PubMed:10852826). Interacts with PKP2 (PubMed:10852826). ; (Microbial infection) Interacts with HCV core protein.
Post-translational modification Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm (PubMed:21465480). Phosphorylated by STK33 (PubMed:18811945). Phosphorylated on tyrosine residues by SRMS (PubMed:29496907). ; O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. ; S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.
Involvement in disease Cataract 30, multiple types (CTRCT30) [MIM:116300]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Note=The disease is caused by variants affecting the gene represented in this entry.
Target Relevance information above includes information from UniProt accession: P08670
The UniProt Consortium

Data

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_1.jpg

Detection of human Vimentin in FFPE HeLa by ICC. Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB.

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_2.jpg

Detection of human Vimentin by western blot. Samples: Whole cell lysate (5 µg) from RKO, HeLa, MCF-7, U2OS, LNCaP, A-549, Hep-G2, HEK293T, and Jurkat cells prepared using NETN lysis buffer. Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG. Detection: Chemiluminescence with an exposure time of 3 seconds. Lower Panel: Rabbit anti-Actin recombinant monoclonal antibody.

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_3.jpg

Detection of human Vimentin in FFPE colon carcinoma by immunohistochemistry-IF. Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: Opal™. Counterstain: DAPI.

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_4.jpg

Detection of human Vimentin in FFPE tonsil by IHC.Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_5.jpg

Detection of human Vimentin in FFPE colon by IHC.Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_6.jpg

Detection of mouse Vimentin in FFPE renal cell carcinoma by IHC.Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB.

benchmarkantibodies.com/wp-content/uploads/2024/03/9046_7.jpg

Detection of mouse Vimentin by western blot. Samples: Whole cell lysate (5 µg) from CH27, C2C12, 70Z/3, BW5147.3, CTLL-2, RenCa, J774A1, NIH 3T3, RAW 264.7, and TCMK-1 cells prepared using NETN lysis buffer. Antibody: Rabbit anti-Vimentin recombinant monoclonal antibody used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG. Detection: Chemiluminescence with an exposure time of 1 second. Lower Panel: Rabbit anti-Actin recombinant monoclonal antibody.

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.